Company: PSTV
Filing Date: 2025-04-01
Form Type: PRER14A
Source: 0001140361-25-011649
Chunk: 41

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-01
Form: PRER14A
Chunk 41
---
, LLC is 200 West Jackson Blvd., Suite 1000, Chicago, IL 60606. The shares of Common Stock issuable upon exercise of the Prefunded Warrants, Series A Warrants and Series B Warrants held by Great Point Capital, LLC are each subject to a beneficial ownership limitation of 9.99% and accordingly, not all shares underlying such warrants are reflected in the table above as being beneficially owned. |

| (7) | Reflects (i) 20,425 shares of Common Stock; (ii) 12,255 shares of Common Stock issuable upon the exercise of Series A common stock purchase warrants to purchase shares of Common Stock issued in the May Offering (the “May 2024 Series A Warrants”); (iii) 12,255 shares of Common Stock issuable upon the exercise of May 2024 Warrants; and (iv) 118,746 shares of Common Stock underlying unvested options to purchase shares of Common Stock held by Dr. Hedrick that will vest within 60 days of March 4, 2025. Dr. Hedrick is the President, Chief Executive Officer and a director of Plus Therapeutics. |

| (8) | Reflects (i) 9,815 shares of Common Stock; (ii) 4,902 shares of Common Stock issuable upon the exercise of May 2024 Series A Warrants; (iii) 4,902 shares of Common Stock issuable upon the exercise of May 2024 Warrants; and (iv) 25,444 shares of Common Stock underlying unvested options to purchase shares of Common Stock held by Mr. Sims that will vest within 60 days of March 4, 2025. Mr. Sims is the Chief Financial Officer of Plus Therapeutics. |

| (9) | Reflects (i) 26,497 shares of Common Stock; (ii) 9,804 shares of Common Stock issuable upon the exercise of May 2024 Series A Warrants; (iii) 9,804 shares of Common Stock issuable upon the exercise of May 2024 Warrants; and (iv) 15,502 shares of Common Stock underlying unvested options to purchase shares of Common Stock held by Mr. Clowes that will vest within 60 days of March 4, 2025. Mr. Clowes is a director of Plus Therapeutics. |

| (10) | Reflects 15,502 shares